Cargando…

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report

INTRODUCTION: Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir but is generally reversible upon discontinuation of treatment. We used therapeutic drug monitoring to investigate the occurrence of hyperbilirubinemia in a 49-year-old Hispanic man infected with HIV, foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uglietti, Alessia, Novati, Stefano, Gulminetti, Roberto, Maserati, Renato
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803830/ https://www.ncbi.nlm.nih.gov/pubmed/20062736 http://dx.doi.org/10.1186/1752-1947-3-9307

Ejemplares similares

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
por: Paolucci, Stefania, et al.
Publicado: (2020)

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia
por: Dorresteijn, Mirrin J., et al.
Publicado: (2023)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
por: Paolucci, Stefania, et al.
Publicado: (2021)

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
por: Panagopoulos, Periklis, et al.
Publicado: (2017)

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis
por: Du, Pengqiang, et al.
Publicado: (2019)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
por: Naidoo, Anushka, et al.
Publicado: (2017)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Atazanavir/ritonavir: QTc prolongation following off-label treatment: case report
Publicado: (2021)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Hyperbilirubinemia with mild COVID-19 patient: A case report
por: Essa, Rawand Abudlrahman, et al.
Publicado: (2021)

An Unusual Case of Rapidly Progressive Hyperbilirubinemia
por: Thornton, Kimberly M., et al.
Publicado: (2013)

Drug-Induced Urinary Stone of Atazanavir Incidentally Found in an Asymptomatic Patient: A Case Report
por: Plawecki, Maëlle, et al.
Publicado: (2023)

Hyperbilirubinemia following lenalidomide administration
por: Azmy, Veronica, et al.
Publicado: (2018)

Correlation between serum vitamin D level and neonatal indirect hyperbilirubinemia
por: Mehrpisheh, Shahrokh, et al.
Publicado: (2018)

Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir
por: Kim, Byunghyun, et al.
Publicado: (2018)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis
por: Marinescu, C. I., et al.
Publicado: (2015)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
por: Choe, Pyoeng Gyun, et al.
Publicado: (2010)

Clinical features and genetic variations of severe neonatal hyperbilirubinemia: Five case reports
por: Lin, Fen, et al.
Publicado: (2022)

KIR-HLA Genotypes in HIV-Infected Patients Lacking Immunological Recovery despite Effective Antiretroviral Therapy
por: Soria, Alessandro, et al.
Publicado: (2011)

Correlation between neonatal hyperbilirubinemia and vitamin D levels: A meta-analysis
por: Huang, Jiayu, et al.
Publicado: (2021)

Correlation between hyperbilirubinemia risk and immune cell mitochondria parameters in neonates with jaundice
por: Wang, Yingying, et al.
Publicado: (2023)

Giant abdominopelvic desmoid tumour herniated trough perineum: a case report
por: Tchangai, Boyodi Katanga, et al.
Publicado: (2021)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

The Spiraling Case of a Yellow Chef: Isolated Hyperbilirubinemia
por: Jiang, Karen, et al.
Publicado: (2018)

Neonatal hyperbilirubinemia
por: Ben, Matteo Dal, et al.
Publicado: (2014)

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C
por: Chin, Paul K. L., et al.
Publicado: (2014)

Of waves and troughs
por: Noll-Hussong, Michael
Publicado: (2014)

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
por: Ceccarelli, Giancarlo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4c6ukh8jmfpre1c6hb3ef95pci